|Each film-coated tablet contains 500 mg metformin hydrochloride, excipients.
Each film-coated tablet contains 850 mg metformin hydrochloride, excipients.
Each film-coated tablet contains 1000 mg metformin hydrochloride, excipients.
|Treatment of type 2 diabetes mellitus, particularly in overweight patients, when dietary management and exercise alone does not result in adequate glycaemic control.
• In adults, Metformin film-coated tablets may be used as monotherapy or in combination with other oral antidiabetic agents or with insulin.
• In children from 10 years of age and adolescents, Metformin film-coated tablets may be used as monotherapy or in combination with insulin.
A reduction of diabetic complications has been shown in overweight type 2 diabetic adult patients treated with metformin as first-line therapy after diet failure.
|• Hypersensitivity to metformin or to any of the excipients.
• Diabetic ketoacidosis, diabetic pre-coma.
• Moderate (stage 3b) and severe renal failure or renal dysfunction (creatinine clearance < 45 ml/min or estimated glomerular filtration rate < 45 ml/min/1.73m2).
• Acute conditions with the potential to alter renal function such as dehydration, severe infection, shock.
• A disease which may cause tissue hypoxia (especially acute disease, or worsening of chronic disease) such as decompensated heart failure, respiratory failure, recent myocardial infarction, shock.
• Hepatic insufficiency, acute alcohol intoxication, alcoholism.
|Box with 30 film-coated tablets of 500 mg (3 blisters x 10 tablets).
Box with 30 film-coated tablets of 850 mg (3 blisters x 10 tablets).
Box with 30 film-coated tablets of 1000 mg in a plastic container.